# Liposomal and Standard Bupivacaine in Thoracic Paravertebral Block for Post-Thoracoscopic Pain

> **NCT06165991** · PHASE4 · RECRUITING · sponsor: **Yongtao Sun** · enrollment: 496 (estimated)

## Conditions studied

- Thoracic Paravertebral Block
- Postoperative Analgesia
- Thoracoscopic Lobectomy

## Interventions

- **DRUG:** GroupB:Liposomal bupivacaine and bupivacaine hydrochloride;
- **DRUG:** Group A: bupivacaine hydrochloride;

## Key facts

- **NCT ID:** NCT06165991
- **Lead sponsor:** Yongtao Sun
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2026-01-30
- **Final completion:** 2026-01-31
- **Target enrollment:** 496 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06165991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06165991, "Liposomal and Standard Bupivacaine in Thoracic Paravertebral Block for Post-Thoracoscopic Pain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06165991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*